A Phase 1 interventional study of FluMist and Placebo in Cancer, sponsored by MedImmune LLC. Completed at 5 sites in United States. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-08-14.
Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to get information about the safety of a flu vaccine spray, called FluMist, in children with cancer. The study is also being done to find out how much and how long the vaccine spray can be found in the nose.
This study is a randomized, double-blind Phase 1 study of FluMist vs. placebo in mild to moderately immunocompromised children 5 to 17 years of age with cancer. The primary objective of this study is to describe the safety of FluMist compared with placebo in mild to moderately immunocompromised children with cancer. The secondary objectives of this study are to describe the immune responses following vaccination with FluMist and to determine the incidence and duration of viral replication following vaccination with FluMist.
The standard 0.5 mL dose of vaccine or placebo was administered intranasally. Patients were evaluated at four visits scheduled between days 3-5, days 7-10, days 14-28, and days 35-42 for viral shedding via nasal swabs. Safety outcomes were collected at study clinic visits or by telephone contact through 42 days post dose. Serious adverse events and significant new medical conditions were collected through 180 days after receipt of investigational product.
Immune responses were measured by detection of influenza-specific antibodies as measured by the standard hemagglutination inhibition (HAI) assay. Influenza-specific serum antibody isotype levels were determined and nasal swab specimens were analyzed for the expression of influenza-specific immunoglobulin A (IgA). Serum was analyzed for its ability to neutralize viral particles from infecting Madin-Darby canine kidney cells (microneutralization). Baseline immunosuppression as measured by expression of T- and B-lymphocyte subsets was compared to immunosuppression at time points after vaccination. The duration of viral replication and the titers of live-attenuated influenza virus shed was evaluated from nasal swab specimens collected at scheduled time points after administration of FluMist.
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 20 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →MedImmune LLC is the lead sponsor of 270 studies on the registry; none are open to participants now.
Of its 52 completed or terminated interventional studies of FDA-regulated products, 29 (56%) have results posted.
First submitted before MedImmune LLC became part of AstraZeneca.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril). Each dose contained approximately 10 to 7th TCID 50 (median tissue culture infectious dose) of each of three influenza virus strains. During the 2005 enrollment period, the three 2004/2005 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/Wyoming/03/2003(H3N2), and B/Jilin/20/2003). During the 2006 and 2007 enrollment periods, the three 2005/2006 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/California/7/2004(H3N2), and B/Jiangsu/10/2003 (B/Shanghai/361/2002-like.
Biological: FluMist
Placebo intranasal mist was composed of allantoic fluid stabilized with buffer containing sucrose, potassium phosphate, and monosodium glutamate. The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
Biological: Placebo
The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril). Each dose contained approximately 10 to 7th TCID 50 (median tissue culture infectious dose) of each of three influenza virus strains. During the 2005 enrollment period, the three 2004/2005 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/Wyoming/03/2003(H3N2), and B/Jilin/20/2003). During the 2006 and 2007 enrollment periods, the three 2005/2006 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/California/7/2004(H3N2), and B/Jiangsu/10/2003 (B/Shanghai/361/2002-like. brief description of the arm. This element may not be necessary if the associated intervention descriptions contain sufficient information to describe the arm.
Placebo intranasal mist was composed of allantoic fluid stabilized with buffer containing sucrose, potassium phosphate, and monosodium glutamate. The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
Number of Participants Who Had Reactogenicity Events (REs)
Reactogenicity events (REs) are predefined solicited adverse events (AEs) that can potentially occur after vaccine administration. The REs for this study included fever, runny nose/nasal congestion, sore throat, cough, vomiting, headache, muscle aches, chills, tiredness, and irritability.
Time frame: 0-42 days after study vaccination
Number of Participants Who Had Serious Adverse Events (SAEs)
An SAE is any AE that results in any of the following outcomes: •Death • Life-threatening • Inpatient hospitalization or prolongation of existing hospitalization • Persistent or significant disability or incapacity • Congenital anomaly/birth defect (in the offspring of a study participant) • An important medical event that may may jeopardize the study participant and may require medical or surgical intervention to prevent one of the outcomes listed above.
Time frame: 0-180 days after study vaccination
Number of Participants Who Had Adverse Events (AEs)
An AE is any untoward medical occurrence in a patient or clinical investigations study participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Time frame: 0-42 days after study vaccination
Number of Significant New Medical Conditions (SNMCs)
A significant new medical condition is defined as a new diagnosis of a chronic medical condition that does not meet the criteria of a SAE.
Time frame: 43-180 days after study vaccination
Number of Participants Shedding Vaccine-like Virus
Number of participants with nasal swab samples that contained vaccine-like virus are reported.
Time frame: 3-5 days after study vaccination
Number of Participants Shedding Vaccine-like Virus
Number of participants with nasal swab samples that contained vaccine-like virus are reported.
Time frame: 7-10 days after study vaccination
Number of Participants Shedding Vaccine-like Virus
Number of participants with nasal swab samples that contained vaccine-like virus are reported.
Time frame: 14-28 days after study vaccination
Number of Participants Shedding Vaccine-like Virus
Number of participants with nasal swab samples that contained vaccine-like virus are reported. Sample was collected at this time point only if health assessment indicated presence of a respiratory illness, including otitis media.
Time frame: 35-42 days after study vaccination
Number of Participants Shedding Vaccine-like Virus
Number of participants with nasal swab samples that contained vaccine-like virus are reported.
Time frame: Unscheduled visits occurring during 0-42 days after study vaccination
T- and B-lymphocyte Subsets by Flow Cytometry - Cluster of Differentiation (CD) 19
Mean and standard deviation results of CD19 lymphocyte subsets as a percentage of total lymphocytes.
Time frame: pre-dosing (Day 0)
T- and B-lymphocyte Subsets by Flow Cytometry - CD3
Mean and standard deviation results of CD3 lymphocyte subsets as a percentage of total lymphocytes.
Time frame: pre-dosing (Day 0)
T- and B-lymphocyte Subsets by Flow Cytometry - CD4
Mean and standard deviation results of CD4 lymphocyte subsets as a percentage of total lymphocytes.
Time frame: pre-dosing (Day 0)
T- and B-lymphocyte Subsets by Flow Cytometry - CD8
Mean and standard deviation results of CD8 lymphocyte subsets as a percentage of total lymphocytes.
Time frame: pre-dosing (Day 0)
T- and B-lymphocyte Subsets by Flow Cytometry - CD19
Mean and standard deviation results of CD19 lymphocyte subsets as a percentage of total lymphocytes.
Time frame: 7-10 days after study vaccination
T- and B-lymphocyte Subsets by Flow Cytometry - CD3
Mean and standard deviation results of CD3 lymphocyte subsets as a percentage of total lymphocytes.
Time frame: 7-10 days after study vaccination
T- and B-lymphocyte Subsets by Flow Cytometry - CD4
Mean and standard deviation results of CD4 lymphocyte subsets as a percentage of total lymphocytes.
Time frame: 7-10 days after study vaccination
T- and B-lymphocyte Subsets by Flow Cytometry - CD8
Mean and standard deviation results of CD8 lymphocyte subsets as a percentage of total lymphocytes.
Time frame: 7-10 days after study vaccination
Interferon (INF)-Gamma
Mean and standard deviation spots-forming cells per 10\^5 T cells is reported.
Time frame: pre-dosing (Day 0)
INF-Gamma
Mean and standard deviation spots-forming cells per 10\^5 T cells is reported.
Time frame: 7-10 days after study vaccination
INF-Gamma
Mean and standard deviation spots-forming cells per 10\^5 T cells is reported.
Time frame: 35-42 days after study vaccination
Interleukin (IL)-4
Mean and standard deviation spots-forming cells per 10\^5 T cells is reported.
Time frame: pre-dosing (Day 0)
IL-4
Mean and standard deviation spots-forming cells per 10\^5 T cells is reported.
Time frame: 7-10 days after study vaccination
IL-4
Mean and standard deviation spots-forming cells per 10\^5 T cells is reported.
Time frame: 35-42 days after study vaccination
Human Leukocyte Antigen (HLA) Matched Tetramers CD8+
The antigen-specific response of the T cell populations was measured using HLA-matched tetramers specific for human CD8 cell populations.
Time frame: pre-dosing (Day 0)
HLA Matched Tetramers CD8+
The antigen-specific response of the T cell populations was measured using HLA-matched tetramers specific for human CD8 cell populations.
Time frame: 7-10 days after study vaccination
HLA Matched Tetramers CD8+
The antigen-specific response of the T cell populations was measured using HLA-matched tetramers specific for human CD8 cell populations.
Time frame: 35-42 days after study vaccination
Number of Participants Who Experienced a >= 4-fold Rise in Serum Influenza A/H1N1 Hemagglutination Inhibition (HAI) Titers From Baseline to Day 35-42
Participants with a geometric mean fold-rise in influenza-specific nasal HAI titers \>= 4 from baseline are reported.
Time frame: Baseline (pre-dosing on Day 0) and 35-42 days after study vaccination
Number of Participants Who Experienced a >= 4-fold Rise in Serum Influenza A/H3N2 HAI Titers From Baseline to Day 35-42
Participants with a geometric mean fold-rise in influenza-specific nasal HAI titers \>= 4 from baseline are reported.
Time frame: Baseline (pre-dosing on Day 0) and 35-42 days after study vaccination
Number of Participants Who Experienced a >= 4-fold Rise in Serum Influenza B HAI Titers From Baseline to Day 35-42
Participants with a geometric mean fold-rise in influenza-specific nasal HAI titers \>= 4 from baseline are reported.
Time frame: Baseline (pre-dosing on Day 0) and 35-42 days after study vaccination
Number of Participants Who Experienced a >= 4-fold Rise in Influenza A/H1N1 Microneutralization Titers From Baseline to Day 35-42
Participants with a geometric mean fold-rise in influenza-specific nasal microneutralization titers \>= 4 from baseline are reported.
Time frame: Baseline (pre-dosing on Day 0) and 35-42 days after study vaccination
Number of Participants Who Experienced a >= 4-fold Rise in Influenza A/H3N2 Microneutralization Titers From Baseline to Day 35-42
Participants with a geometric mean fold-rise in influenza-specific nasal microneutralization titers \>= 4 from baseline are reported.
Time frame: Baseline (pre-dosing on Day 0) and 35-42 days after study vaccination
Number of Participants Who Experienced a >= 4-fold Rise in Influenza B Microneutralization Titers From Baseline to Day 35-42
Participants with a geometric mean fold-rise in influenza-specific nasal microneutralization titers \>= 4 from baseline are reported.
Time frame: Baseline (pre-dosing on Day 0) and 35-42 days after study vaccination
Influenza A/H1N1 Immunoglobulin A (IgA)
Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
Time frame: pre-dosing (Day 0)
Influenza A/H1N1 IgA
Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
Time frame: 3-5 days after study vaccination
Influenza A/H1N1 IgA
Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
Time frame: 7-10 days after study vaccination
Influenza A/H1N1 IgA
Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
Time frame: 14-28 days after study vaccination
Influenza A/H1N1 IgA
Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
Time frame: 35-42 days after study vaccination
Influenza A/H3N2 IgA
Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
Time frame: pre-dosing (Day 0)
Influenza A/H3N2 IgA
Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
Time frame: 3-5 days after study vaccination
Influenza A/H3N2 IgA
Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
Time frame: 7-10 days after study vaccination
Influenza A/H3N2 IgA
Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
Time frame: 14-28 days after study vaccination
Influenza A/H3N2 IgA
Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
Time frame: 35-42 days after study vaccination
Influenza B IgA
Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
Time frame: pre-dosing (Day 0)
Influenza B IgA
Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
Time frame: 3-5 days after study vaccination
Influenza B IgA
Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
Time frame: 7-10 days after study vaccination
Influenza B IgA
Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
Time frame: 14-28 days after study vaccination
Influenza B IgA
Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
Time frame: 35-42 days after study vaccination
T- and B-lymphocyte Subsets by Flow Cytometry - CD56
Mean and standard deviation results of CD56 lymphocyte subsets is reported.
Time frame: pre-dosing (Day 0)
T- and B-lymphocyte Subsets by Flow Cytometry - CD56
Mean and standard deviation results of CD56 lymphocyte subsets is reported.
Time frame: 7-10 days after study vaccination
T- and B-lymphocyte Subsets by Flow Cytometry - White Blood Cells
Mean and standard deviation results of white blood cells subsets is reported.
Time frame: pre-dosing (Day 0)
T- and B-lymphocyte Subsets by Flow Cytometry - White Blood Cells
Mean and standard deviation results of white blood cells subsets is reported.
Time frame: 7-10 days after study vaccination
T- and B-lymphocyte Subsets by Flow Cytometry - Lymphocytes
Mean and standard deviation results of lymphocytes subsets is reported.
Time frame: pre-dosing (Day 0)
T- and B-lymphocyte Subsets by Flow Cytometry - Lymphocytes
Mean and standard deviation results of lymphocytes subsets is reported.
Time frame: 7-10 days after study vaccination
T- and B-lymphocyte Subsets by Flow Cytometry - Absolute Lymphocytes
Mean and standard deviation results of absolute lymphocytes subsets is reported.
Time frame: pre-dosing (Day 0)
T- and B-lymphocyte Subsets by Flow Cytometry - Absolute Lymphocytes
Mean and standard deviation results of absolute lymphocytes subsets is reported.
Time frame: 7-10 days after study vaccination
T- and B-lymphocyte Subsets by Flow Cytometry - Absolute Neutrophils
Mean and standard deviation results of absolute neutrophils subsets is reported.
Time frame: pre-dosing (Day 0)
Influenza A/H1N1 Immunoglobulin G (IgG)
Mean of influenza-specific IgG from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
Time frame: pre-dosing (Day 0)
Influenza A/H1N1 IgG
Mean of influenza-specific IgG from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
Time frame: 35-42 days after study vaccination
Influenza A/H3N2 IgG
Mean of influenza-specific IgG from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
Time frame: pre-dosing (Day 0)
Influenza A/H3N2 IgG
Mean of influenza-specific IgG from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
Time frame: 35-42 days after study vaccination
Influenza B IgG
Mean of influenza-specific IgG from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
Time frame: pre-dosing (Day 0)
Influenza B IgG
Mean of influenza-specific IgG from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
Time frame: 35-42 days after study vaccination
Influenza A/H1N1 Immunoglobulin M (IgM)
Mean of influenza-specific IgM from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
Time frame: pre-dosing (Day 0)
Influenza A/H1N1 IgM
Mean of influenza-specific IgM from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
Time frame: 35-42 days after study vaccination
Influenza A/H3N2 IgM
Mean of influenza-specific IgM from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
Time frame: pre-dosing (Day 0)
Influenza A/H3N2 IgM
Mean of influenza-specific IgM from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
Time frame: 35-42 days after study vaccination
Influenza B IgM
Mean of influenza-specific IgM from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
Time frame: pre-dosing (Day 0)
Influenza B IgM
Mean of influenza-specific IgM from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
Time frame: 35-42 days after study vaccination
A total of 20 participants, 10 in the FluMist group and 10 in the placebo group, were enrolled in the study between 08Aug2005 and 31Mar2008 at 4 sites in the USA.
| Milestone | Placebo | FluMist |
|---|---|---|
| Started | 10 | 10 |
| Completed | 10 | 10 |
| Not completed | 0 | 0 |
Reactogenicity events (REs) are predefined solicited adverse events (AEs) that can potentially occur after vaccine administration. The REs for this study included fever, runny nose/nasal congestion, sore throat, cough, vomiting, headache, muscle aches, chills, tiredness, and irritability.
| participants | FluMist | Placebo |
|---|---|---|
| Number of Participants Who Had Reactogenicity Events (REs) | 8 | 9 |
An SAE is any AE that results in any of the following outcomes: •Death • Life-threatening • Inpatient hospitalization or prolongation of existing hospitalization • Persistent or significant disability or incapacity • Congenital anomaly/birth defect (in the offspring of a study participant) • An important medical event that may may jeopardize the study participant and may require medical or surgical intervention to prevent one of the outcomes listed above.
| Participants | FluMist | Placebo |
|---|---|---|
| Number of Participants Who Had Serious Adverse Events (SAEs) | 1 | 3 |
An AE is any untoward medical occurrence in a patient or clinical investigations study participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
| participants | FluMist | Placebo |
|---|---|---|
| Number of Participants Who Had Adverse Events (AEs) | 6 | 10 |
A significant new medical condition is defined as a new diagnosis of a chronic medical condition that does not meet the criteria of a SAE.
| events | FluMist | Placebo |
|---|---|---|
| Number of Significant New Medical Conditions (SNMCs) | 0 | 0 |
Number of participants with nasal swab samples that contained vaccine-like virus are reported.
| participants | FluMist | Placebo |
|---|---|---|
| Number of Participants Shedding Vaccine-like Virus | 3 | 0 |
Number of participants with nasal swab samples that contained vaccine-like virus are reported.
| participants | FluMist | Placebo |
|---|---|---|
| Number of Participants Shedding Vaccine-like Virus | 2 | 0 |
Number of participants with nasal swab samples that contained vaccine-like virus are reported.
| participants | FluMist | Placebo |
|---|---|---|
| Number of Participants Shedding Vaccine-like Virus | 0 | 0 |
Number of participants with nasal swab samples that contained vaccine-like virus are reported. Sample was collected at this time point only if health assessment indicated presence of a respiratory illness, including otitis media.
| participants | FluMist | Placebo |
|---|---|---|
| Number of Participants Shedding Vaccine-like Virus | 0 | 0 |
Number of participants with nasal swab samples that contained vaccine-like virus are reported.
| participants | FluMist | Placebo |
|---|---|---|
| Number of Participants Shedding Vaccine-like Virus | — | 0 |
Mean and standard deviation results of CD19 lymphocyte subsets as a percentage of total lymphocytes.
| percentage of lymphocytes | FluMist | Placebo |
|---|---|---|
| T- and B-lymphocyte Subsets by Flow Cytometry - Cluster of Differentiation (CD) 19 | 8.6 ± 7.4 | 4.8 ± 8.3 |
Mean and standard deviation results of CD3 lymphocyte subsets as a percentage of total lymphocytes.
| percentage of lymphocytes | FluMist | Placebo |
|---|---|---|
| T- and B-lymphocyte Subsets by Flow Cytometry - CD3 | 83.6 ± 8.9 | 89.1 ± 10.3 |
Mean and standard deviation results of CD4 lymphocyte subsets as a percentage of total lymphocytes.
| percentage of lymphocytes | FluMist | Placebo |
|---|---|---|
| T- and B-lymphocyte Subsets by Flow Cytometry - CD4 | 47.3 ± 9.8 | 46.7 ± 7.5 |
Mean and standard deviation results of CD8 lymphocyte subsets as a percentage of total lymphocytes.
| percentage of lymphocytes | FluMist | Placebo |
|---|---|---|
| T- and B-lymphocyte Subsets by Flow Cytometry - CD8 | 31.4 ± 8.1 | 38.8 ± 7.8 |
Mean and standard deviation results of CD19 lymphocyte subsets as a percentage of total lymphocytes.
| percentage of lymphocytes | FluMist | Placebo |
|---|---|---|
| T- and B-lymphocyte Subsets by Flow Cytometry - CD19 | 10.2 ± 10.8 | 5.1 ± 8.6 |
Mean and standard deviation results of CD3 lymphocyte subsets as a percentage of total lymphocytes.
| percentage of lymphocytes | FluMist | Placebo |
|---|---|---|
| T- and B-lymphocyte Subsets by Flow Cytometry - CD3 | 82.0 ± 9.9 | 89.9 ± 11.6 |
Mean and standard deviation results of CD4 lymphocyte subsets as a percentage of total lymphocytes.
| percentage of lymphocytes | FluMist | Placebo |
|---|---|---|
| T- and B-lymphocyte Subsets by Flow Cytometry - CD4 | 48.2 ± 11.8 | 46.5 ± 11.4 |
Mean and standard deviation results of CD8 lymphocyte subsets as a percentage of total lymphocytes.
| percentage of lymphocytes | FluMist | Placebo |
|---|---|---|
| T- and B-lymphocyte Subsets by Flow Cytometry - CD8 | 27.9 ± 8.0 | 39.6 ± 10.1 |
Mean and standard deviation spots-forming cells per 10\^5 T cells is reported.
| cells per 10^5 T cells | FluMist | Placebo |
|---|---|---|
| Interferon (INF)-Gamma | 17.0 ± 27.2 | 16.5 ± 25.9 |
Mean and standard deviation spots-forming cells per 10\^5 T cells is reported.
| cells per 10^5 T cells | FluMist | Placebo |
|---|---|---|
| INF-Gamma | 28.6 ± 43.7 | 7.5 ± 7.6 |
Mean and standard deviation spots-forming cells per 10\^5 T cells is reported.
| cells per 10^5 T cells | FluMist | Placebo |
|---|---|---|
| INF-Gamma | 28.0 ± 38.7 | 16.6 ± 27.0 |
Mean and standard deviation spots-forming cells per 10\^5 T cells is reported.
| cells per 10^5 T cells | FluMist | Placebo |
|---|---|---|
| Interleukin (IL)-4 | 2.6 ± 4.3 | 5.5 ± 8.4 |
Mean and standard deviation spots-forming cells per 10\^5 T cells is reported.
| cells per 10^5 T cells | FluMist | Placebo |
|---|---|---|
| IL-4 | 1.9 ± 2.7 | 2.6 ± 3.5 |
Mean and standard deviation spots-forming cells per 10\^5 T cells is reported.
| cells per 10^5 T cells | FluMist | Placebo |
|---|---|---|
| IL-4 | 2.9 ± 3.9 | 4.7 ± 6.1 |
The antigen-specific response of the T cell populations was measured using HLA-matched tetramers specific for human CD8 cell populations.
| Percentage of lymphocytes | FluMist | Placebo |
|---|---|---|
| Human Leukocyte Antigen (HLA) Matched Tetramers CD8+ | 11.045 ± 6.452 | 12.778 ± 6.579 |
The antigen-specific response of the T cell populations was measured using HLA-matched tetramers specific for human CD8 cell populations.
| Percentage of lymphocytes | FluMist | Placebo |
|---|---|---|
| HLA Matched Tetramers CD8+ | 8.048 ± 6.701 | 8.632 ± 4.126 |
The antigen-specific response of the T cell populations was measured using HLA-matched tetramers specific for human CD8 cell populations.
| Percentage of lymphocytes | FluMist | Placebo |
|---|---|---|
| HLA Matched Tetramers CD8+ | 7.997 ± 3.143 | 12.922 ± 8.607 |
Participants with a geometric mean fold-rise in influenza-specific nasal HAI titers \>= 4 from baseline are reported.
| participants | FluMist | Placebo |
|---|---|---|
| Number of Participants Who Experienced a >= 4-fold Rise in Serum Influenza A/H1N1 Hemagglutination Inhibition (HAI) Titers From Baseline to Day 35-42 | 1 | 0 |
Participants with a geometric mean fold-rise in influenza-specific nasal HAI titers \>= 4 from baseline are reported.
| participants | FluMist | Placebo |
|---|---|---|
| Number of Participants Who Experienced a >= 4-fold Rise in Serum Influenza A/H3N2 HAI Titers From Baseline to Day 35-42 | 2 | 0 |
Participants with a geometric mean fold-rise in influenza-specific nasal HAI titers \>= 4 from baseline are reported.
| participants | FluMist | Placebo |
|---|---|---|
| Number of Participants Who Experienced a >= 4-fold Rise in Serum Influenza B HAI Titers From Baseline to Day 35-42 | 1 | 0 |
Participants with a geometric mean fold-rise in influenza-specific nasal microneutralization titers \>= 4 from baseline are reported.
| participants | FluMist | Placebo |
|---|---|---|
| Number of Participants Who Experienced a >= 4-fold Rise in Influenza A/H1N1 Microneutralization Titers From Baseline to Day 35-42 | 2 | 0 |
Participants with a geometric mean fold-rise in influenza-specific nasal microneutralization titers \>= 4 from baseline are reported.
| participants | FluMist | Placebo |
|---|---|---|
| Number of Participants Who Experienced a >= 4-fold Rise in Influenza A/H3N2 Microneutralization Titers From Baseline to Day 35-42 | 2 | 0 |
Participants with a geometric mean fold-rise in influenza-specific nasal microneutralization titers \>= 4 from baseline are reported.
| participants | FluMist | Placebo |
|---|---|---|
| Number of Participants Who Experienced a >= 4-fold Rise in Influenza B Microneutralization Titers From Baseline to Day 35-42 | 1 | 0 |
Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
| titer | FluMist | Placebo |
|---|---|---|
| Influenza A/H1N1 Immunoglobulin A (IgA) | 0.8 ± 0.8 | 0.5 ± 0.0 |
Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
| titer | FluMist | Placebo |
|---|---|---|
| Influenza A/H1N1 IgA | 0.8 ± 0.7 | 0.5 ± 0.0 |
Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
| titer | FluMist | Placebo |
|---|---|---|
| Influenza A/H1N1 IgA | 1.1 ± 1.1 | 0.5 ± 0.0 |
Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
| titer | FluMist | Placebo |
|---|---|---|
| Influenza A/H1N1 IgA | 0.9 ± 0.9 | 1.1 ± 1.3 |
Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
| titer | FluMist | Placebo |
|---|---|---|
| Influenza A/H1N1 IgA | 1.3 ± 1.3 | 0.5 ± 0.0 |
Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
| titer | FluMist | Placebo |
|---|---|---|
| Influenza A/H3N2 IgA | 1.0 ± 0.8 | 0.7 ± 0.5 |
Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
| titer | FluMist | Placebo |
|---|---|---|
| Influenza A/H3N2 IgA | 0.7 ± 0.5 | 0.5 ± 0.0 |
Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
| titer | FluMist | Placebo |
|---|---|---|
| Influenza A/H3N2 IgA | 1.2 ± 0.8 | 0.7 ± 0.5 |
Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
| titer | FluMist | Placebo |
|---|---|---|
| Influenza A/H3N2 IgA | 0.7 ± 0.5 | 1.1 ± 0.9 |
Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
| titer | FluMist | Placebo |
|---|---|---|
| Influenza A/H3N2 IgA | 1.7 ± 1.0 | 0.5 ± 0.0 |
Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
| titer | FluMist | Placebo |
|---|---|---|
| Influenza B IgA | 0.5 ± 0.0 | 0.5 ± 0.0 |
Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
| titer | FluMist | Placebo |
|---|---|---|
| Influenza B IgA | 0.5 ± 0.0 | 0.5 ± 0.0 |
Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
| titer | FluMist | Placebo |
|---|---|---|
| Influenza B IgA | 0.5 ± 0.0 | 0.5 ± 0.0 |
Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
| titer | FluMist | Placebo |
|---|---|---|
| Influenza B IgA | 0.5 ± 0.0 | 0.5 ± 0.0 |
Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
| titer | FluMist | Placebo |
|---|---|---|
| Influenza B IgA | 0.7 ± 0.5 | 0.5 ± 0.0 |
Mean and standard deviation results of CD56 lymphocyte subsets is reported.
| percent of lymphocytes | FluMist | Placebo |
|---|---|---|
| T- and B-lymphocyte Subsets by Flow Cytometry - CD56 | 7.6 ± 5.5 | 5.2 ± 3.2 |
Mean and standard deviation results of CD56 lymphocyte subsets is reported.
| percent of lymphocytes | FluMist | Placebo |
|---|---|---|
| T- and B-lymphocyte Subsets by Flow Cytometry - CD56 | 6.6 ± 5.6 | 4.6 ± 3.4 |
Mean and standard deviation results of white blood cells subsets is reported.
| cells per 10^3/UL | FluMist | Placebo |
|---|---|---|
| T- and B-lymphocyte Subsets by Flow Cytometry - White Blood Cells | 3.91 ± 1.56 | 4.19 ± 1.49 |
Mean and standard deviation results of white blood cells subsets is reported.
| cells per 10^3/UL | FluMist | Placebo |
|---|---|---|
| T- and B-lymphocyte Subsets by Flow Cytometry - White Blood Cells | 4.05 ± 1.33 | 3.24 ± 1.10 |
Mean and standard deviation results of lymphocytes subsets is reported.
| Percentage of lymphocytes | FluMist | Placebo |
|---|---|---|
| T- and B-lymphocyte Subsets by Flow Cytometry - Lymphocytes | 27.56 ± 9.25 | 17.62 ± 7.56 |
Mean and standard deviation results of lymphocytes subsets is reported.
| Percentage of lymphocytes | FluMist | Placebo |
|---|---|---|
| T- and B-lymphocyte Subsets by Flow Cytometry - Lymphocytes | 23.13 ± 8.23 | 22.58 ± 11.89 |
Mean and standard deviation results of absolute lymphocytes subsets is reported.
| Cells per 10^3/UL | FluMist | Placebo |
|---|---|---|
| T- and B-lymphocyte Subsets by Flow Cytometry - Absolute Lymphocytes | 1.03 ± 0.50 | 0.77 ± 0.51 |
Mean and standard deviation results of absolute lymphocytes subsets is reported.
| Cells per 10^3/UL | FluMist | Placebo |
|---|---|---|
| T- and B-lymphocyte Subsets by Flow Cytometry - Absolute Lymphocytes | 0.98 ± 0.57 | 0.77 ± 0.58 |
Mean and standard deviation results of absolute neutrophils subsets is reported.
| Cells per 10^3/UL | FluMist | Placebo |
|---|---|---|
| T- and B-lymphocyte Subsets by Flow Cytometry - Absolute Neutrophils | 2728.6 ± 1162.9 | 3300.0 ± 1534.6 |
Mean of influenza-specific IgG from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
| titer | FluMist | Placebo |
|---|---|---|
| Influenza A/H1N1 Immunoglobulin G (IgG) | 672.4 ± 492.8 | 954.7 ± 1245.3 |
Mean of influenza-specific IgG from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
| titer | FluMist | Placebo |
|---|---|---|
| Influenza A/H1N1 IgG | 844.0 ± 645.7 | 924.3 ± 1207.2 |
Mean of influenza-specific IgG from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
| titer | FluMist | Placebo |
|---|---|---|
| Influenza A/H3N2 IgG | 1842.4 ± 1989.1 | 799.1 ± 426.2 |
Mean of influenza-specific IgG from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
| titer | FluMist | Placebo |
|---|---|---|
| Influenza A/H3N2 IgG | 1671.9 ± 1646.6 | 742.9 ± 432.2 |
Mean of influenza-specific IgG from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
| titer | FluMist | Placebo |
|---|---|---|
| Influenza B IgG | 638.6 ± 334.5 | 599.1 ± 344.2 |
Mean of influenza-specific IgG from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
| titer | FluMist | Placebo |
|---|---|---|
| Influenza B IgG | 1020.3 ± 715.6 | 620.2 ± 472.8 |
Mean of influenza-specific IgM from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
| titer | FluMist | Placebo |
|---|---|---|
| Influenza A/H1N1 Immunoglobulin M (IgM) | 160.4 ± 105.4 | 150.1 ± 107.0 |
Mean of influenza-specific IgM from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
| titer | FluMist | Placebo |
|---|---|---|
| Influenza A/H1N1 IgM | 134.8 ± 100.7 | 171.3 ± 106.7 |
Mean of influenza-specific IgM from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
| titer | FluMist | Placebo |
|---|---|---|
| Influenza A/H3N2 IgM | 134.7 ± 100.4 | 153.1 ± 109.4 |
Mean of influenza-specific IgM from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
| titer | FluMist | Placebo |
|---|---|---|
| Influenza A/H3N2 IgM | 136.9 ± 103.1 | 189.9 ± 98.5 |
Mean of influenza-specific IgM from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
| titer | FluMist | Placebo |
|---|---|---|
| Influenza B IgM | 72.2 ± 66.7 | 69.3 ± 61.0 |
Mean of influenza-specific IgM from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.
| titer | FluMist | Placebo |
|---|---|---|
| Influenza B IgM | 68.4 ± 55.3 | 82.0 ± 69.7 |
Collected over Adverse events were collected from the time of investigational product administration through Day 42. Serious adverse events were collected from the time of study drug administration through Day 180.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 3/10 (30%) | 9/10 (90%) |
| FluMist | — | 1/10 (10%) | 5/10 (50%) |
| Event | Placebo | FluMist |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 2/10 | 0/10 |
| BacteraemiaInfections and infestations | 1/10 | 0/10 |
| Herpes zosterInfections and infestations | 1/10 | 0/10 |
| PneumoniaInfections and infestations | 1/10 | 0/10 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/10 | 1/10 |
| Event | Placebo | FluMist |
|---|---|---|
| RashSkin and subcutaneous tissue disorders | 2/10 | 0/10 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/10 | 0/10 |
| ConjunctivitisEye disorders | 1/10 | 0/10 |
| Abdominal pain upperGastrointestinal disorders | 1/10 | 0/10 |
| ConstipationGastrointestinal disorders | 0/10 | 1/10 |
| DiarrhoeaGastrointestinal disorders | 1/10 | 0/10 |
| DyspepsiaGastrointestinal disorders | 1/10 | 0/10 |
| NauseaGastrointestinal disorders | 1/10 | 0/10 |
| Oral painGastrointestinal disorders | 1/10 | 0/10 |
| Fungal skin infectionInfections and infestations | 1/10 | 0/10 |
| Age, Continuous(Years) | Placebo | FluMist | Total |
|---|---|---|---|
| Mean | 12.2 ± 3.8 | 12.2 ± 3.9 | 12.2 ± 3.8 |
| Sex: Female, Male(Participants) | Placebo | FluMist | Total |
|---|---|---|---|
| Female | 4 | 7 | 11 |
| Male | 6 | 3 | 9 |
Ran from Aug 2005 to primary completion in Mar 2008, 31 months.
Results were first posted in Sep 2012, 4 years 6 months after primary completion.
Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's 31 months is below that.
Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: FluMist